<DOC>
	<DOCNO>NCT00876187</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety multiple dos tanezumab administer every 8 week treat chronic low back pain . Tanezumab monoclonal antibody direct human nerve growth factor .</brief_summary>
	<brief_title>A Study Tanezumab Adults With Chronic Low Back Pain</brief_title>
	<detailed_description />
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<criteria>Present duration low back pain ≥3 month require regular use analgesic medication ( &gt; 4 day per week past month ) . Analgesic medication may consist NSAIDs , selective COX2 inhibitor , immediate release opioids , combination , certain protocoldefined limitation . Primary location low back pain must 12th thoracic vertebra low gluteal fold , without radiation posterior thigh Must meet criterion pain severity global assessment low back pain Screening Baseline visit Female patient childbearing potential ( male patient female partner childbearing potential ) must use 2 method contraception throughout study Patients must willing discontinue pain medication chronic low back pain except rescue medication use prohibit pain medication throughout duration study History lumbosacral radiculopathy within past 2 year . Back pain due visceral disorder ( eg , endometriosis ) . Back pain due major trauma osteoporotic compression fracture past 6 month . History rheumatoid arthritis , seronegative spondyloarthropathy , Paget 's disease spine , pelvis femur ; fibromyalgia ; tumor infections spinal cord . Surgical intervention past 6 month treatment low back pain plan surgical intervention course study . Current pending worker 's compensation , litigation , disability , monetary settlement regard his/her CLBP pain condition , close claim within past 5 year . Use analgesic muscle relaxant within 48 hour prior five day Baseline Patients receive acetaminophen , gabapentin pregabalin manage chronic low back pain . Patients take &gt; 325 mg/day aspirin . Use antidepressants exception stable treatment selective serotonin reuptake inhibitor ( SSRIs ) . Use sedatives/hypnotics , anxiolytic , tranquilizer , benzodiazepine unless daily dose stable remain unchanged throughout study period . Systemic corticosteroid therapy within 30 day ( inhaled topical corticosteroid permit ) . Local epidural injection corticosteroid , well injection corticosteroid back within 3 month . Botulinum toxin ( Botox® ) injection chronic low back pain within 4 month . Requirement new , concomitant physiotherapy include , limited , transdermal electroneural stimulation ( TENS ) , massage spinal manipulation duration study period . Active suspect esophageal , gastric , pyloric channel , duodenal ulceration within 3 month , history gastrointestinal bleeding . Current use lithium anticoagulant agent . Known hypersensitivity intolerance NSAIDs ; history asthma , urticaria , allergic type reaction take aspirin NSAIDs . Inflammatory bowel disease , chronic acute renal hepatic disorder , significant coagulation defect , condition might preclude use NSAID . History intolerance acetaminophen paracetamol excipients . History known alcohol , analgesic narcotic abuse within 2 year . Presence drug abuse ( include prescription medication without valid prescription ) , illegal drug marijuana urine toxicology screen obtain Screening . History allergic anaphylactic reaction therapeutic diagnostic monoclonal antibody IgG fusion protein . Use biologics study medication , include live vaccine , within 3 month , use study ( intranasal Flumist® vaccine exception ) . Signs symptom clinically significant cardiac disease . Diagnosis transient ischemic attack within 6 month , residual deficit stroke would preclude completion require study activity . History cancer within 5 year . Use investigational medication within 30 day ( 3 month investigational biologics ) . Expected undergo therapeutic procedure use analgesic specify protocol throughout study period . Previous exposure exogenous NGF anti NGF antibody . Screening laboratory result blood pressure within specify limit . Positive Hepatitis B , Hepatitis C , human immunodeficiency virus ( HIV ) test screen . History , diagnosis , sign symptom clinically significant neurological disease . History , diagnosis , sign symptom clinically significant psychiatric disorder . Hospital admission depression suicide attempt within 5 year active , severe major depression Screening . Likelihood non compliant study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>randomize control trial</keyword>
	<keyword>monoclonal antibody</keyword>
	<keyword>nerve growth factor</keyword>
	<keyword>naproxen</keyword>
</DOC>